Improvement in insulin sensitivity during mifepristone treatment of Cushing syndrome: early and late effects
- PMID: 23970725
- PMCID: PMC3747910
- DOI: 10.2337/dc13-0246
Improvement in insulin sensitivity during mifepristone treatment of Cushing syndrome: early and late effects
References
-
- Pivonello R, De Leo M, Vitale P, et al. Pathophysiology of diabetes mellitus in Cushing’s syndrome. Neuroendocrinology 2010;92(Suppl. 1):77–81 - PubMed
-
- Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 2011;96:632–642 - PubMed
-
- Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C, SEISMIC Study Investigators Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome. J Clin Endocrinol Metab 2012;97:2039–2049 - PubMed
-
- Albareda M, Rodríguez-Espinosa J, Murugo M, de Leiva A, Corcoy R. Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test. Diabetologia 2000;43:1507–1511 - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
